Antipsoriatic Small Molecule Development Services

The advent of novel small-molecule therapies has broadened the therapeutic landscape for psoriasis, providing new avenues for intervention. At Ace Therapeutics, we specialize in the development of antipsoriatic small molecules and provide comprehensive support throughout the drug discovery process.

Overview of Antipsoriatic Small Molecules

Antipsoriatic small molecules are designed to interfere with specific biological targets implicated in the development and progression of psoriasis. Key pathways in the disease include the IL-17/IL-23 axis, TNF-alpha signaling pathways, and various kinase pathways. Small molecules can inhibit these critical signaling molecules, thereby reducing inflammation and abnormal keratinocyte proliferation.

Recent advancements in understanding the immunopathogenesis of psoriasis have facilitated the identification of novel therapeutic targets. For instance, the discovery of selective inhibitors of the Tyk2 pathway has led to the development of deucravacitinib, the first oral allosteric Tyk2 inhibitor approved for moderate to severe psoriasis.

Fig. 1 Main inflammatory pathways involved in psoriasis pathogenesis and potential therapeutic targets. (Carmona-Rocha E, et al., 2024)

Customized Antipsoriatic Small Molecule Development Services

At Ace Therapeutics, we provide end-to-end small molecule development services tailored to your specific needs. Our services encompass the entire drug discovery pipeline, from target identification and validation to lead optimization and preclinical studies.

Psoriasis Target Identification and Validation

• Identify psoriasis-related molecular targets using advanced genomic and proteomic techniques.
• Validate targets through experimental assays, confirming their role in psoriasis pathogenesis.

Small Molecule Screening and Optimization for Psoriasis

• High-throughput screening of small molecule libraries against validated psoriasis targets.
• Structure-activity relationship (SAR) studies to enhance compound potency, selectivity, and drug-like properties.

In Vitro Anti-Psoriatic Efficacy Evaluation

• Assess the cell-based cytotoxicity of small molecule drug candidates using cell viability assays on psoriasis-like PHKs and HaCaT human keratinocytes.
• Evaluate anti-inflammatory activity by measuring cytokine (e.g., TNF-α, IL-17A, IL-23, IL-22, IL-8, IL-6) release from stimulated keratinocytes and immune cells using ELISA.
• Study effects on skin cell growth via keratinocyte proliferation assays.
• Investigate the impact on key psoriasis-related pathways (e.g., JAK/STAT, NF-κB) using immunocytochemistry and western blotting.
• Assess the expression of psoriasis markers (e.g., KRT17, GLUT1, BD2) using qPCR and immunocytochemistry.

In Vivo Anti-Psoriatic Efficacy Evaluation

• Evaluate the efficacy of lead compounds in established animal models of psoriasis.
• Assess pharmacodynamic effects, including reduction of psoriatic lesions and systemic inflammation.

Pharmacokinetics and Toxicology Studies

• Determine the absorption, distribution, metabolism, and excretion (ADME) profiles of small molecules through pharmacokinetic studies.
• Evaluate safety profiles through toxicological assessments, including dose-ranging studies.

Our Advantages in Antipsoriatic Small Molecule Development Services

• Expertise and Experience: With a team of seasoned scientists and researchers, Ace Therapeutics brings extensive knowledge in dermatological research and small-molecule drug development.
• Integrated Drug Discovery Pipeline: Our end-to-end drug discovery pipeline allows for seamless transitions from target discovery to preclinical evaluation.
• Customized Development Pathways: Our flexible approach allows for the optimization of small molecule candidates based on specific mechanistic insights and the unique characteristics of psoriasis subtypes.

Unlock the potential of antipsoriatic small molecules with Ace Therapeutics. Our dedicated team is ready to support your research and development needs. Contact us today to discuss how we can help you advance your psoriasis therapeutic projects and bring innovative treatments to the forefront.